Hereditary Angioedema - Global Strategic Business Report

The global market for Hereditary Angioedema was valued at USD 3.5 Billion in 2024 and is projected to reach USD 5.5 Billion by 2030, growing at a CAGR of 7.7% from 2024 to 2030. This comprehensive report provides an in-depth analysis of market trends, drivers, and forecasts, helping you make informed business decisions.

Global Hereditary Angioedema (HAE) Market - Key Trends & Drivers Summarized

What Is Hereditary Angioedema, and Why Is Treatment Demand Rising?

Hereditary angioedema (HAE) is a rare genetic disorder characterized by recurrent episodes of severe swelling, often affecting the skin, gastrointestinal tract, and airways. These attacks can be life-threatening, particularly when swelling affects the throat or airways, making effective management crucial. As awareness of HAE grows, more patients are receiving accurate diagnoses and treatments, increasing demand for therapies that can prevent and control these attacks. Early diagnosis and access to specialized treatments are essential for improving quality of life and reducing emergency interventions for HAE patients.

How Are New Therapeutics Improving HAE Management?

Advancements in HAE therapeutics, particularly preventive and acute treatment options, are transforming patient care. Therapies such as C1 esterase inhibitors, kallikrein inhibitors, and monoclonal antibodies specifically target the underlying causes of HAE, effectively reducing attack frequency and severity. Prophylactic treatments, in particular, enable patients to manage their condition proactively, preventing severe attacks and reducing hospital visits. These therapies are improving outcomes for HAE patients, allowing them to live with fewer disruptions and enhancing overall quality of life.

What Role Does Patient Support and Advocacy Play in Market Growth?

Patient support groups and advocacy organizations play a significant role in increasing awareness and driving access to HAE treatments. By educating patients and healthcare providers on the symptoms, risks, and available therapies, these organizations help patients seek timely treatment and participate in clinical trials. Advocacy efforts have also led to improved insurance coverage for expensive HAE treatments, making them more accessible. This community support is essential for advancing treatment options and ensuring that patients have the resources needed for effective HAE management.

What Drives the Growth of the Hereditary Angioedema Market?

The growth in the hereditary angioedema market is driven by increased awareness, advancements in targeted therapies, and strong patient advocacy efforts. Growing awareness enables earlier diagnosis and treatment, expanding the patient base for HAE therapeutics. Targeted therapies, including preventive options, are transforming HAE management, offering patients more effective and proactive treatment choices. Additionally, advocacy organizations are supporting access and awareness, helping to secure insurance coverage and enhance patient care. These factors collectively support market growth, as HAE management becomes increasingly accessible and effective for patients globally.

Report Scope

The report analyzes the Hereditary Angioedema market, presented in terms of market value (USD Thousand). The analysis covers the key segments and geographic regions outlined below.

Segments

Drug Class (C1 Esterase Inhibitors, Selective Bradykinin B2 Receptor Antagonists, Kallikrein Inhibitors, Other Drug Classes); Route of Administration (Subcutaneous Injections, Intravenous, Oral); Distribution Channel (Retail Pharmacies, Hospital Pharmacies, Other Distribution Channels).

Geographic Regions/Countries

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; and Rest of Europe); Asia-Pacific; Rest of World.

Key Insights:

• Market Growth: Understand the significant growth trajectory of the C1 Esterase Inhibitors segment, which is expected to reach $2.5 Billion by 2030 with a CAGR of a 8.2%. The Selective Bradykinin B2 Receptor Antagonists segment is also set to grow at 6.9% CAGR over the analysis period.
• Regional Analysis: Gain insights into the U.S. market, valued at $974 Million in 2024, and China, forecasted to grow at an impressive 7.1% CAGR to reach $849.3 Million by 2030. Discover growth trends in other key regions, including Japan, Canada, Germany, and the Asia-Pacific.

Report Features:

• Comprehensive Market Data: Independent analysis of annual sales and market forecasts in USD from 2024 to 2030.
• In-Depth Regional Analysis: Detailed insights into key markets, including the U.S., China, Japan, Canada, Europe, Asia-Pacific, Latin America, Middle East, and Africa.
• Company Profiles: Coverage of major players such as BioCryst Pharmaceuticals, Inc., CSL Ltd., iBio, Inc., Ionis Pharmaceuticals, Inc., Pharming Group NV and more.
• Complimentary Updates: Receive free report updates for one year to keep you informed of the latest market developments.

Why You Should Buy This Report:

• Detailed Market Analysis: Access a thorough analysis of the Global Hereditary Angioedema Market, covering all major geographic regions and market segments.
• Competitive Insights: Get an overview of the competitive landscape, including the market presence of major players across different geographies.
• Future Trends and Drivers: Understand the key trends and drivers shaping the future of the Global Hereditary Angioedema Market.
• Actionable Insights: Benefit from actionable insights that can help you identify new revenue opportunities and make strategic business decisions.

Key Questions Answered:

• How is the Global Hereditary Angioedema Market expected to evolve by 2030?
• What are the main drivers and restraints affecting the market?
• Which market segments will grow the most over the forecast period?
• How will market shares for different regions and segments change by 2030?
• Who are the leading players in the market, and what are their prospects?

Some of the 46 major companies featured in this Hereditary Angioedema market report include:

• BioCryst Pharmaceuticals, Inc.
• CSL Ltd.
• iBio, Inc.
• Ionis Pharmaceuticals, Inc.
• Pharming Group NV
• Shire PLC